FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive: Future work will expand the panel of CML cell lines, FLT-3-ITD mutated AML and other common subtypes and incorporate lymphoid leukemia models to enable a more comprehensive comparison across hematologic lineages to assess the generalizability potential of the observed signaling dynamics.